Global Glioblastoma Multiforme Therapeutics Market 2015-2019

About Glioblastoma Multiforme
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor. 

Glioblastoma multiforme is the most common variant of brain tumor, and highly invasive in nature. It may turn up in the cerebrum, mostly in the frontal and temporal lobes, and seldom spreads in areas outside the brain. The tumor progresses rapidly, and is among the most difficult-to-treat cancer with limited treatment options. 

Glioblastoma multiforme is also known as Class IV astrocytoma which has an unknown etiology, and is more frequent in men than women. Some of the common symptoms of glioblastoma multiforme are increased intracranial pressure resulting in nausea, vomiting, and headache, cognitive and visual impairment, motor dysfunction, seizures, loss in sensory functions, and changes in personality, mood or concentration. The condition can be broadly classified into two types, primary or de novo glioblastoma multiforme (which progresses very fast) and secondary glioblastoma multiforme (which is known to progress at a slower rate). Glioblastoma multiforme can be treated by chemotherapy, steroids, radiation therapy, proton therapy, surgical procedure, and immunotherapies, which are the emerging treatment options yet to hit the market. 

Technavio analysts forecast the global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019.

Covered in this Report
The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. 

Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Oral
• Parenteral 

Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows:
• Small Molecules
• Biologics

This report includes a discussion on the market in the following three regions: 
• The Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries, such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

The Technavio report, namely Global Glioblastoma Multiforme Therapeutics Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. The report covers the Americas, and EMEA and APAC markets. It presents the market landscape and its growth prospects in the coming years.

Key Regions
• Americas 
• EMEA        
• APAC

Key Vendors
• Arbor Pharmaceuticals
• Bristol-Myers Squibb
• Eisai
• F. Hoffmann-La Roche
• Merck  

Other Prominent Vendors
• AB Science
• Abbvie
• Actelion
• Activartis Biotech
• Advantagene
• Agenus
• Agios
• Amgen
• Angiochem
• Apogenix
• Axelar
• BioNTech
• Boehringer Ingelheim
• Boston Biomedical
• Bristol-Myers Squibb
• Celgene
• Celldex Therapeutics
• ChemoCentryx
• Cortice Biosciences
• CytoVac
• CytRx
• Deciphera 
• Del Mar Pharmaceuticals
• Diffusion Pharmaceuticals 
• DNATrix
• Eli Lilly
• Epitopoietic Research 
• e-Therapeutics
• Exelixis
• G W Pharmaceuticals
• Genspera
• immatics  
• ImmunoCellular Therapeutics
• Immunovaccine
• Intrexon
• IRAD Oncology
• Karyopharm Therapeutics
• Kite Pharma
• Life Science Pharmaceuticals
• Medicenna Therapeutics
• Merck
• Merrimack Pharmaceuticals
• Nektar Therapeutics
• Northwest Biotherapeutics 
• Novartis
• Noxxon
• OncoSynergy
• Oncovir
• Ono Pharmaceutical
• Peregrine Pharmaceuticals
• Plexxikon
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemline Therapeutics
• Tocagen
• Tracon Pharma
• TVAX Biomedical
• VBL Therapeutics
• Virttu Biologics 
• Ziopharm Oncology

Market Driver
• Lack of Treatment Options for Glioblastoma Multiforme
• For a full and detailed list, view our report

Market Challenge
• Use of Off-label Drugs
• For a full and detailed list, view our report

Market Trend
• Prospective Entry of Novel Agents
• For a full and detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?